Edition:
United States

Guerbet SA (GRBT.PA)

GRBT.PA on Paris Stock Exchange

74.06EUR
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
€74.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
7,213
52-wk High
€90.64
52-wk Low
€65.50

Chart for

About

Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents... (more)

Overall

Beta: 0.53
Market Cap(Mil.): €1,061.47
Shares Outstanding(Mil.): 12.50
Dividend: 0.85
Yield (%): 1.00

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Guerbet Updates On MHLW Decision In Japan

* HAS IMMEDIATELY PROCEEDED TO REQUESTED REVISION OF PRECAUTIONS FOR MAGNESCOPE Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Dec 06 2017

BRIEF-Guerbet 9 months revenue up at ‍​601.4 million euros

* 9 MONTHS REVENUE AT CURRENT EXCHANGE RATE EUR ‍​601.4 MILLION VERSUS EUR 568.4 MILLION YEAR AGO

Oct 25 2017

BRIEF-Guerbet H1 net income up at 23.1 million euros

* H1 NET INCOME EUR 23.1 MILLION VERSUS EUR 12.1 MILLION YEAR AGO

Sep 26 2017

BRIEF-Guerbet announces CE mark for Vectorio

* REG-GUERBET ANNOUNCES CE MARK FOR VECTORIO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Sep 14 2017

BRIEF-FDA approves Guerbet’S Dotarem for patients younger than two years‍​

* FDA APPROVES GUERBET’S DOTAREM (GADOTERATE MEGLUMINE) FOR PEDIATRIC PATIENTS YOUNGER THAN TWO YEARS‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Sep 05 2017

BRIEF-Guerbet H1 revenue rises to 407.1 million euros

* H1 REVENUE EUR 407.1 MILLION VERSUS EUR 376.7 MILLION YEAR AGO

Jul 27 2017

BRIEF-Guerbet to phase out Hexabrix and Optimark sales globally

* WILL PHASE OUT SALES THROUGHOUT WORLD OF TWO PRODUCTS: HEXABRIX® (MEGLUMINE AND SODIUM IOXAGLATE) AND OPTIMARK® (GADOVERSETAMIDE).

Jul 10 2017

BRIEF-Guerbet invests in Truffle Capital Fund

* GUERBET INVESTS IN TRUFFLE CAPITAL FUND DEDICATED TO MEDICAL DEVICES AND BIOTECHNOLOGIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 14 2017

Earnings vs. Estimates